Analysts say completing the negotiations represents significant further upside potential for the company, which is focussed on addressing iron deficiency.
According to Peel Hunt, the reviewed data are also supportive of the existing EU and Chinese commercial partners’ marketing efforts.
Late on Thursday, the specialty pharmaceutical firm released findings of a reanalysis of the AEGIS-H2H study, indicating that Feraccru/Accrufer is a credible alternative to IV therapy for iron deficiency anaemia and corrects anaemia and maintains iron levels over the long term.
“Feraccru’s comparable improvement in haemoglobin in the long-term data against IV, combined with its greater tolerability, significantly more convenient oral administration, and compelling economic benefits, constitutes a very strong marketing package for EU commercialisation partner Norgine to leverage into the market,” analysts commented.
Peel Hunt pointed out that many intravenous (IV) patients needed expensive re-administrations, meaning Shield’s drug is a cheaper alternative.
“We believe this will have positive implications for health economic outcomes, pricing strategies and partnering opportunities,” analysts at Edison Group added.
“The next key inflection point is a US partnering deal; we expect Accrufer launch later this year once a partner has been found.”